T. Rowe Price Associates
ATRS

T. Rowe Price Associates’s Antares Pharma, Inc. ATRS Stock Holding History

T. Rowe Price Associates’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-81,560
Closed -$334K – 3038
2022
Q1 		$334K Buy
81,560
+36,303
+80% +$132K ﹤0.01% 2512
2021
Q4 		$162K Sell
45,257
-3,200
-7% -$11.2K ﹤0.01% 2804
2021
Q3 		$176K Buy
48,457
+815
+2% +$3.29K ﹤0.01% 2753
2021
Q2 		$208K Buy
47,642
+20,094
+73% +$81.9K ﹤0.01% 2717
2021
Q1 		$113K Buy
27,548
+16,312
+145% +$70.7K ﹤0.01% 2772
2020
Q4 		$45K Sell
11,236
-600
-5% -$1.94K ﹤0.01% 2652
2020
Q3 		$32K Hold
11,836
– – ﹤0.01% 2565
2020
Q2 		$33K Buy
11,836
+608
+5% +$1.7K ﹤0.01% 2476
2020
Q1 		$26K Buy
11,228
+1,038
+10% +$3.53K ﹤0.01% 2481
2019
Q4 		$48K Buy
+10,190
New +$41.7K ﹤0.01% 2496

Other funds holding ATRS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's ATRS Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 81,560 shares — an estimated $334K sold.

T. Rowe Price Associates first reported a position in ATRS in Q4 2019 and held it in 10 quarters. The position peaked at $334K in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 81,560 Antares Pharma, Inc. shares in Q2 2022, an estimated $334K.
  • T. Rowe Price Associates first reported a position in Antares Pharma, Inc. in Q4 2019 and held it in 10 quarters.
  • T. Rowe Price Associates's Antares Pharma, Inc. position peaked at $334K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.